Who is sponsoring NCT04366505?

NCT04366505 is sponsored by Central Institute of Mental Health, Mannheim.

What drugs are being tested in NCT04366505?

Interventions in NCT04366505: Treatment as usual (TAU) and neurofeedback (NFB), mindfulness-based relapse prevention (MBRP) and NFB, TAU and sham NFB, MBT and sham NFB.

What condition does NCT04366505 study?

NCT04366505 studies Alcohol Use Disorder (AUD).

Is NCT04366505 still recruiting?

NCT04366505 is currently status unknown. Last updated 28 April 2021.

Last reviewed 2021-04-28 · How we verify

NCT04366505

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Modification of Cue Reactivity by Neurofeedback in Human Addiction

Status unknown NA Last updated 28 April 2021

What this trial tests

NA trial testing Treatment as usual (TAU) and neurofeedback (NFB) in Alcohol Use Disorder (AUD) in 88 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	Central Institute of Mental Health, Mannheim
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	88
Start date	1 July 2021
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	1 location across Germany

Drugs / interventions tested

Treatment as usual (TAU) and neurofeedback (NFB)
mindfulness-based relapse prevention (MBRP) and NFB
TAU and sham NFB
MBT and sham NFB

Conditions studied

Alcohol Use Disorder (AUD) — all drugs for Alcohol Use Disorder (AUD) →

Sponsor

Central Institute of Mental Health, Mannheim

Who can join

Adults 21 to 60, any sex, with Alcohol Use Disorder (AUD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project is geared towards the understanding of how to increase cognitive control over cue reactivity and drug craving.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Using mind control to modify cue-reactivity in AUD: the impact of mindfulness-based relapse prevention on real-time fMRI neurofeedback to modify cue-reactivity in alcohol use disorder: a randomized controlled trial.
Weiss F, Aslan A, Zhang J, Gerchen MF, et al · · 2020 · cited 8× · PMID 32546139 · DOI 10.1186/s12888-020-02717-7

Verify or expand the search:

Other recruiting trials for Alcohol Use Disorder (AUD)

Currently open trials in the same condition.

NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption · Phase 2 · recruiting
NCT07040592 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide · Phase 2 · recruiting
NCT06949423 — Assessing the Impact of dTMS on Neural Targets Associated With Alcohol Use Disorder · NA · recruiting
NCT06070649 — The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) · Phase 1 · recruiting
NCT06335407 — Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study · Phase 1 · recruiting

Other Central Institute of Mental Health, Mannheim trials

Trials by the same sponsor.

NCT06845124 — A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence · Phase 2 · recruiting
NCT00916201 — Evaluation Study of New Compounds With Potential Use in Schizophrenia · Phase 1 · withdrawn
NCT06959342 — Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treat · NA · recruiting
NCT06881810 — Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment · Phase 2 · recruiting
NCT05726045 — Increasing Smoking Cessation Success Through Sleep-amplified Memory Consolidation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04366505 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Institute of Mental Health, Mannheim
Last refreshed: 28 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04366505.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing